

Genetic Risk Factors & Cardiovascular Disease

Bibliography of One Hundred Key Papers

selected by **R. Sanders Williams, MD; Pascal J. Goldschmidt-Clermont, MD**
Duke University Medical Center - Durham, NC - USA

-
- Abbott GW, Sesti F, Splawski I, et al.** *MiRP1 forms I_{Kr} potassium channels with HERG and is associated with cardiac arrhythmia.*
Cell. 1999;97:175-187.
-
- Arber S, Hunter JJ, Ross J Jr, et al.** *MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure.*
Cell. 1997;88:393-403.
-
- Bala S, Peltomaki P.** *CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer.*
Cancer Res. 2001;61:6042-6045.
-
- Balmain A.** *Cancer: new-age tumour suppressors.*
Nature. 2002;417:235-237.
-
- Balmain A, Harris CC.** *Carcinogenesis in mouse and human cells: parallels and paradoxes.*
Carcinogenesis. 2000;21:371-317.
-
- Balmain A, Nagase H.** *Cancer resistance genes in mice: models for the study of tumour modifiers.*
Trends Genet. 1998;14:139-144.
-
- Basson CT, Bachinsky DR, Lin RC, et al.** *Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome.*
Nat Genet. 1997;15:30-35.
-
- Benson DW, Silberbach GM, Kavanaugh-McHugh A, et al.** *Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways.*
J Clin Invest. 1999;104:1567-1573.
-
- Bodmer R.** *The gene tinman is required for specification of the heart and visceral muscles in Drosophila.*
Development. 1993;118:719-729.
-
- Bray PF, Cannon CP, Goldschmidt-Clermont P, et al.** *The platelet P1(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.*
Am J Cardiol. 2001;88:347-352.
-
- Bray PF, Weiss EJ, Tayback M, Goldschmidt-Clermont PJ.** *PIA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease.*
Lancet. 1997;349:1100-1101.
-

Bibliography of One Hundred Key Papers

- Breslow JL.** *Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility.*
Annu Rev Genet. 2000;34:233-254.
-
- Brugada R, Tapscott T, Czernuszewicz GZ, et al.** *Identification of a genetic locus for familial atrial fibrillation.*
N Engl J Med. 1997;336:905-911.
-
- Cavenee WK, Dryja TP, Phillips RA, et al.** *Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.*
Nature. 1983;305:779-784.
-
- Chakravarti A.** *To a future of genetic medicine.*
Nature. 2001;409:822-823.
-
- Cohen BA, Mitra RD, Hughes JD, Church GM.** *A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression.*
Nat Genet. 2000;26:183-186.
-
- Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ.** *PLA2 polymorphism and efficacy of aspirin.*
Lancet. 1998;351:1253.
-
- Coral-Vazquez R, Cohn RD, Moore SA, et al.** *Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy.*
Cell. 1999;98:465-474.
-
- Cormier RT, Bilger A, Lillich AJ, et al.** *The Mom1AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64.*
Oncogene. 2000;19:3182-3192.
-
- Cormier RT, Hong KH, Halberg RB, et al.** *Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis.*
Nat Genet. 1997;17:88-91.
-
- Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT.** *The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis.*
Cell. 1993;73:159-168.
-
- Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT.** *A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.*
Cell. 1995;80:795-803.
-
- Darvasi A.** *Experimental strategies for the genetic dissection of complex traits in animal models.*
Nat Genet. 1998;18:19-24.
-
- Davies K.** **Cracking the Genome.** New York, NY: The Free Press; 2001.
-
- Dietrich WF, Lander ES, Smith JS, et al.** *Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse.*
Cell. 1993;75:631-639.
-
- Dietz HC, Cutting GR, Pyeritz RE, et al.** *Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.*
Nature. 1991;352:337-339.
-
- Dong C, Nevins JR, Goldschmidt-Clermont PJ.** *ABCA1 single nucleotide polymorphisms. Snipping at the pathogenesis of atherosclerosis.*
Circ Res. 2001;88:855-857.
-



-
- Emery AE.** *The muscular dystrophies.*
Lancet. 2002;359:687-695.
-
- Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ.** *The murine gene p27Kip1 is haplo-insufficient for tumour suppression.*
Nature. 1998;396:177-180.
-
- Fijneman RJ, de Vries SS, Jansen RC, Demant P.** *Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse.*
Nat Genet. 1996;14:465-467.
-
- Fijneman RJ, Jansen RC, van der Valk MA, Demant P.** *High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14.*
Cancer Res. 1998;58:4794-4798.
-
- Flint J, Mott R.** *Finding the molecular basis of quantitative traits: successes and pitfalls.*
Nat Rev Genet. 2001;2:437-445.
-
- Florentz C, Sissler M.** *Disease-related versus polymorphic mutations in human mitochondrial tRNAs. Where is the difference?*
EMBO Rep. 2001;2:481-486.
-
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al.** *A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.*
Cell. 1990;62:999-1006.
-
- Geller DS, Farhi A, Pinkerton N, et al.** *Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.*
Science. 2000;289:119-123.
-
- Goldbourt U, Neufeld HN.** *Genetic aspects of arteriosclerosis.*
Arteriosclerosis. 1986;6:357-377.
-
- Goldschmidt-Clermont P, Roos C, Cooke GE.** *Platelet P1A2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.*
J Thromb Thrombolysis. 2000;8:89-103.
-
- Goldschmidt-Clermont PJ, Cooke GE, Eaton GM, Binkley PF.** *PIA2, a variant of GPIIIa implicated in coronary thromboembolic complications.*
J Am Coll Cardiol. 2000;36:90-93.
-
- Goldstein JL, Brown MS.** *Molecular medicine. The cholesterol quartet.*
Science. 2001;292:1310-1312.
-
- Gollob MH, Seger JJ, Gollob TN, et al.** *Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy.*
Circulation. 2001;104:3030-3033.
-
- Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, et al.** *Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease*
N Engl J Med. 2002;346:967-974.
-

Bibliography of One Hundred Key Papers

- Higashi MK, Veenstra DL, Kondo LM, et al.** Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA*. 2002;287:1690-1698.
-
- Hill JA, Rothermel B, Yoo KD, et al.** Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. *J Biol Chem*. 2002;277:10251-10255.
-
- Hixson JE, Blangero J.** Genomic searches for genes that influence atherosclerosis and its risk factors. *Ann N Y Acad Sci*. 2000;902:1-7.
-
- Hobbs HH, Leitersdorf E, Goldstein JL, Brown MS, Russell DW.** Multiple crm-mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions. *J Clin Invest*. 1988;81:909-917.
-
- Hobbs HH, Russell DW, Brown MS, Goldstein JL.** The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. *Annu Rev Genet*. 1990;24:133-170.
-
- Hu FL, Gu Z, Kozich V, Kraus JP, Ramesh V, Shih VE.** Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. *Hum Mol Genet*. 1993;2:1857-1860.
-
- Kandzari DE, Goldschmidt-Clermont PJ.** Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. *J Am Coll Cardiol*. 2001;38:1028-1032.
-
- Kastrati A, Koch W, Gawaz M, et al.** P1A polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. *J Am Coll Cardiol*. 2000;36:84-89.
-
- Kastrati A, Schomig A, Seyfarth M, et al.** P1A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. *Circulation*. 1999;99:1005-1010.
-
- Keating MT, Sanguinetti MC.** Molecular and cellular mechanisms of cardiac arrhythmias. *Cell*. 2001;104:569-580.
-
- Khogali SS, Mayosi BM, Beattie JM, McKenna WJ, Watkins H, Poulton J.** A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. *Lancet*. 2001;357:1265-1267.
-
- Kiechl S, Lorenz E, Reindl M, et al.** Toll-like receptor 4 polymorphisms and atherogenesis. *N Engl J Med*. 2002;347:185-192.
-
- Kruglyak L.** Genetic isolates: separate but equal? *Proc Natl Acad Sci USA*. 1999;96:1170-1172.
-
- Kruglyak L.** Prospects for whole-genome linkage disequilibrium mapping of common disease genes. *Nat Genet*. 1999;22:139-144.
-
- Laule M, Cascorbi I, Stangl V, et al.** A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. *Lancet*. 1999;353:708-712.
-



-
- Liggett SB, Wagoner LE, Craft LL, et al.** *The Ile164 beta₂-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.*
J Clin Invest. 1998;102:1534-1539.
-
- Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U.** *Genetic susceptibility to death from coronary heart disease in a study of twins.*
N Engl J Med. 1994;330:1041-1046.
-
- McCully KS.** *Homocysteine and vascular disease.*
Nat Med. 1996;2:386-389.
-
- Michelson AD, Furman MI, Goldschmidt-Clermont P, et al.** *Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.*
Circulation. 2000;101:1013-1018.
-
- Mikkelsson J, Perola M, Kauppila LI, et al.** *The GPIIIa Pl(A) polymorphism in the progression of abdominal aortic atherosclerosis.*
Atherosclerosis. 1999;147:55-60.
-
- Minamisawa S, Hoshijima M, Chu G, et al.** *Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.*
Cell. 1999;99:313-322.
-
- Molkentin JD, Lu JR, Antos CL, Markham B, et al.** *A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.*
Cell. 1998;93:215-228.
-
- Murata M, Kawano K, Matsubara Y, Ishikawa K, Watanabe K, Ikeda Y.** *Genetic polymorphisms and risk of coronary artery disease.*
Semin Thromb Hemost. 1998;24:245-250.
-
- Olson EN, Williams RS.** *Calcineurin signaling and muscle remodeling.*
Cell. 2000;101:689-692.
-
- Ponder BA.** *Cancer genetics.*
Nature. 2001;411:336-341.
-
- Psaty BM, Smith NL, Heckbert SR, et al.** *Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension.*
JAMA. 2002;287:1680-1689.
-
- Reich DE, Cargill M, Bolk S, et al.** *Linkage disequilibrium in the human genome.*
Nature. 2001;411:199-204.
-
- Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K.** *PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.*
Lancet. 1997;349:385-388.
-
- Rissanen AM.** *Familial occurrence of coronary heart disease: effect of age at diagnosis.*
Am J Cardiol. 1979;44:60-66.
-
- Rockman HA, Chien KR, Choi DJ, et al.** *Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.*
Proc Natl Acad Sci USA. 1998;95:7000-7005.
-
- Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS.** *A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling.*
J Biol Chem. 2000;275:8719-8725.
-

Bibliography of One Hundred Key Papers

- Rothermel BA, McKinsey TA, Vega RB, et al.** *Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.*
Proc Natl Acad Sci USA. 2001;98:3328-3333.
-
- Russell DW, Lehrman MA, Sudhof TC, et al.** *The LDL receptor in familial hypercholesterolemia: use of human mutations to dissect a membrane protein.*
Cold Spring Harb Symp Quant Biol. 1986;51(pt 2):811-819.
-
- Scott HS, Litjens T, Hopwood JJ, Morris CP.** *A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype.*
Hum Mutat. 1992;1:103-108.
-
- Sesti F, Abbott GW, Wei J, et al.** *A common polymorphism associated with antibiotic-induced cardiac arrhythmia.*
Proc Natl Acad Sci USA. 2000;97:10613-10618.
-
- Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A.** *Family history as an independent risk factor for coronary artery disease.*
J Am Coll Cardiol. 1984;4:793-801.
-
- Simon DB, Nelson-Williams C, Bia MJ, et al.** *Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter.*
Nat Genet. 1996;12:24-30.
-
- Smith JD, Dansky HM, Breslow JL.** *Genetic modifiers of atherosclerosis in mice.*
Ann N Y Acad Sci. 2001;947:247-252; discussion 252-253.
-
- Snyder PM, Price MP, McDonald FJ, et al.** *Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na⁺ channel.*
Cell. 1995;83:969-978.
-
- Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ.** *Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.*
Proc Natl Acad Sci USA. 1989;86:587-591.
-
- Splawski I, Shen J, Timothy KW, et al.** *Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.*
Circulation. 2000;102:1178-1185.
-
- Steinmetz LM, Sinha H, Richards DR, et al.** *Dissecting the architecture of a quantitative trait locus in yeast.*
Nature. 2002;416:326-330.
-
- Suzuki M, Carlson KM, Marchuk DA, Rockman HA.** *Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy.*
Circulation. 2002;105:1824-1829.
-
- Undas A, Brummel K, Musial J, Mann KG, Szczeklik A.** *PI(A2) polymorphism of beta₃ integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury.*
Circulation. 2001;104:2666-2672.
-
- Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF.** *The PI(A2) polymorphism of integrin beta₃ enhances outside-in signaling and adhesive functions.*
J Clin Invest. 2000;105:793-802.
-



-
- Wallace DC.** *Mitochondrial defects in cardiomyopathy and neuromuscular disease.*
Am Heart J. 2000;139(2 pt 3):S70-S85.
-
- Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM.** *Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis.*
Lancet. 1997;350:1217-1219.
-
- Walter DH, Schachinger V, Elsner M, et al.** *Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the P1(A2) allele of the platelet glycoprotein IIIa gene.*
Eur Heart J. 2001;22:587-595.
-
- Wang J, Freeman DJ, Grundy SM, Levine DM, Guerra R, Cohen JC.** *Linkage between cholesterol 7-alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations.*
J Clin Invest. 1998;101:1283-1291.
-
- Wang Q, Shen J, Splawski I, et al.** *SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome.*
Cell. 1995;80:805-811.
-
- Weiss EJ, Bray PF, Tayback M, et al.** *A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.*
N Engl J Med. 1996;334:1090-1094.
-
- West M, Blanchette C, Dressman H, et al.** *Predicting the clinical status of human breast cancer by using gene expression profiles.*
Proc Natl Acad Sci USA. 2001;98:11462-11467.
-
- Williams RS.** *Calcium-dependent gene regulation in myocyte hypertrophy and remodeling. In:*
Cold Spring Harbor Symposia on Quantitative Biology—The Cardiovascular System; 2002; Cold Spring Harbor, NY; 2002.
-
- Winkelmann BR, Hager J, Kraus WE, et al.** *Genetics of coronary heart disease: current knowledge and research principles.*
Am Heart J. 2000;140:S11-S26.
-
- Yamamoto T, Davis CG, Brown MS, et al.** *The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA.*
Cell. 1984;39:27-38.
-
- Zhang L, Timothy KW, Vincent GM, et al.** *Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes.*
Circulation. 2000;102:2849-2855.
-
- Zhu MM, Weedon J, Clark LT.** *Meta-analysis of the association of platelet glycoprotein IIIa P1A1/A2 polymorphism with myocardial infarction.*
Am J Cardiol. 2000;86:1000-1005. A8.
-
- Zolk O, Caroni P, Bohm M.** *Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure.*
Circulation. 2000;101:2674-2677.
-

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with **three hard copies (text and figures)** printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- **All texts should be submitted in English.** In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—hard copies and on disk, where possible) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All **illustrations should be cited** in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International (SI)** units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals “the Vancouver style.* *Ann Intern Med.* 1997;126:36-47). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg.* 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation.* 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza.* Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting:** all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher's editorial dept according to the specifications of the current edition of the **American Medical Association Manual of Style, Williams & Wilkins**. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial dept will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial dept and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.

- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction of existing work, it is the author's responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

EDITORIAL

The editorial should not exceed 2 **standard typed pages** (maximum 600 words).

LEAD ARTICLE

The lead article should not exceed 25 **standard typed pages** (maximum 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of **10 references of “seminal papers”** as well as a separate list of **100 Key References** should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 25 **standard typed pages** (maximum 2500 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. **No figures, tables or references should be included** in seminal paper summaries.